Research programme: antibody drug conjugate therapeutics - Henlius/Nuolin Biomedical Technology
Alternative Names: Antibody drug conjugate therapeutics - Henlius/Nuolin Biomedical TechnologyLatest Information Update: 25 Mar 2022
At a glance
- Originator Henlius Biopharmaceuticals; Nuolin Biomedical Technology
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer